As of September 18, 2026, BAYERCROP is trading at ₹3771.0, and the daily technical picture indicates a bearish trend. This is supported by the price being below key daily moving averages (EMA 20, EMA 50, SMA 20, SMA 50, SMA 200) and the Supertrend indicator pointing downwards. The weekly timeframe also shows a bearish trend with the price below its weekly moving averages and Supertrend. However, the monthly timeframe presents a conflicting signal, with the Supertrend indicator suggesting a bullish trend, although the price is below its monthly EMA 20 and SMA 20.

Nearest resistance is observed at ₹3801.6, approximately 0.81% above the current price. Support levels are not explicitly provided in the data. Recent market activity includes a "volume_with_price_move" anomaly on September 18, 2026, characterized by extreme downward movement and a high volume ratio of 5.7, alongside a downward gap on September 11, 2026. The stock's current drawdown is -0.42, with annualized volatility at 26%.

Key conditions to watch include the price's ability to overcome the nearest resistance at ₹3801.6. A sustained move above this level could signal a shift in the short-term technical stance. Conversely, a break below recent lows, especially on increased volume, would reinforce the prevailing bearish trend across daily and weekly timeframes.

Bayer CropScience's financial performance shows a mixed trend. While the company reported a significant increase in cash flow from operating activities, rising from ₹433 crore in March 2019 to ₹666 crore in March 2020, and a corresponding jump in free cash flow from ₹378 crore to ₹638 crore over the same period, its compounded sales growth for the trailing twelve months (TTM) was negative at -3%. However, compounded profit growth for the TTM was a strong 24%, and 5-year compounded profit growth stood at 7%. The balance sheet indicates an increase in equity capital from ₹34 crore to ₹45 crore and a rise in reserves from ₹2,205 crore to ₹2,528 crore between March 2019 and March 2020. Investments also saw a substantial increase, from ₹0 crore to ₹41 crore in the same period, while borrowings remained minimal at ₹2 crore in March 2020. Technical indicators suggest a bearish trend on a daily and weekly basis, with the Supertrend indicator at 4038.26 and 4418.4 respectively, and the ADX at 37.78 on the daily chart indicating strong trend momentum. However, the monthly trend shows a bullish Supertrend at 2782.12 with a lower ADX of 15.09.

Bayer CropScience (BAYERCROP) on the NSE experienced a price decrease between its previous observation and the current report date of September 18, 2026. The price moved from ₹3893.4 to ₹3771.0. No new filings or news were reported for the company during this period. The company's profile and exchange listing remain unchanged.

Bayer CropScience Limited's financial position shows a notable increase in total assets from ₹3,549 crore in March 2019 to ₹3,836 crore in March 2020. This growth is accompanied by a rise in equity capital from ₹34 crore to ₹45 crore and reserves from ₹2,205 crore to ₹2,528 crore over the same period. The company's cash flow from operating activities significantly increased to ₹666 crore in March 2020 from ₹433 crore in March 2019, contributing to a higher free cash flow of ₹638 crore compared to ₹378 crore in the prior year. While borrowings remained minimal at ₹2 crore in March 2020, investments increased to ₹41 crore from ₹0. The company's compounded profit growth over 5 years was 7%, with a TTM (Trailing Twelve Months) growth of 24%, contrasting with a TTM sales growth of -3% over the same 5-year period which saw compounded sales growth of 6%.

Technically, as of September 18, 2026, the daily trend indicates a bearish sentiment with the Supertrend indicator at ₹4,038.26. Moving averages such as the 20-day EMA (₹3,977.64) and 50-day SMA (₹4,106.84) are also above the current closing price of ₹3,771.0. The weekly trend also shows a bearish Supertrend at ₹4,418.4. However, the monthly trend shows a bullish Supertrend at ₹2,782.12, suggesting a potential divergence in longer-term outlooks. The stock has experienced significant negative returns across various periods, with a 1-year return of -27% and a year-to-date return of -17%. The current drawdown is -42%.

Bayer CropScience's recent operating performance shows a mixed trajectory. For the fiscal year ending March 2024, the company reported sales of ₹5,106 crore, a slight decrease from ₹5,140 crore in the prior year. Operating profit for the same period was ₹959 crore, up from ₹924 crore year-on-year, indicating an improvement in operating margins to 19.0% from 18.0%. Net profit, however, saw a decline to ₹740 crore in FY24 from ₹758 crore in FY23.

Looking ahead, projections for the fiscal year ending March 2025 indicate an increase in sales to ₹5,473 crore and operating profit to ₹691 crore, though this represents a decrease in operating profit margin to 13.0%. Net profit is estimated to fall to ₹568 crore. For the fiscal year ending March 2026, sales are projected to reach ₹5,675 crore, with operating profit expected to rise to ₹874 crore and net profit to ₹689 crore, with an operating margin of 15.0% and a net profit margin of approximately 12.1%.

Financially, the company's borrowings have decreased from ₹74 crore in March 2023 to ₹47 crore in March 2024. Equity capital has remained stable at ₹45 crore from March 2022 to March 2026. Free cash flow was ₹912 crore in FY24, a significant increase from ₹537 crore in FY23, but is projected to decrease to ₹222 crore in FY25 before rising to ₹1,014 crore in FY26. The company's return on equity has been strong, reported at 24% for the last year.

Bayer CropScience has demonstrated a significant increase in its cash flow from operations, rising from ₹433.0 in March 2019 to ₹666.0 in March 2020. This growth in operating cash flow has contributed to a substantial rise in free cash flow, which increased from ₹378.0 to ₹638.0 over the same period. The company also saw its equity capital grow from ₹34.0 in March 2019 to ₹45.0 in March 2020, alongside an increase in reserves from ₹2205.0 to ₹2528.0. Investments also saw a notable increase, from ₹0 in March 2019 to ₹41.0 in March 2020.

The company's financial performance shows a recent sales decline, with Compounded Sales Growth at -3% for the Trailing Twelve Months (TTM), contrasting with a positive 6% over five years. While profit growth has been stronger at 24% TTM and 7% over five years, the recent sales trend warrants attention. Operationally, cash flow from operations has decreased to ₹666.0 in March 2020 from ₹433.0 in March 2019, though the metric 'CFO/OP' saw a decline from 132.0 to 110.0 over the same periods. The company's balance sheet shows an increase in borrowings to ₹2 crore in March 2020 from ₹0 in March 2019, alongside a rise in Capital Work In Progress (CWIP) to ₹56 crore from ₹47 crore and investments from ₹0 to ₹41 crore. Technical indicators suggest a bearish trend on a daily timeframe, with the Supertrend indicator at 4038.26 and the 14-day ADX at 37.78, indicating strong bearish momentum. Weekly trends also show a bearish Supertrend direction at 4418.4.